Literature DB >> 27420920

Minireview: Regulatory T Cells and Ovarian Cancer.

Manindra Singh1, Tiffany Loftus2, Erin Webb2, Fabian Benencia1,2.   

Abstract

In the last 15 years, it has become apparent that ovarian cancer is recognized by the immune system, taking into account that T cell infiltration can be associated with increased overall survival. Several studies indicate that a correct combination of cluster of differentiation 8 and cluster of differentiation 4 T cells is key to fight tumor progression and that the presence of regulatory T cells (Tregs) infiltrating ovarian solid tumors (or present in ascites) is deleterious. Several markers that characterize Tregs include glucocorticoid-induced tumor necrosis factor receptor, cytotoxic T lymphocyte antigen-4, and forkhead box protein 3 (Foxp3). Research has shown that Tregs can infiltrate cancerous tissue and contribute to tumor growth by secreting immunosuppressive cytokines such as transforming growth factor beta and interleukin (IL)-10. Importantly, these cells might hamper the efficacy of immunotherapeutic approaches, thus strategies involving depletion or regulation of this population have been proposed and tested in experimental models. In this Minireview, we will discuss the relevance of Tregs in ovarian cancer and the experimental approaches destined to impair their immunosuppressive effects.

Entities:  

Keywords:  Ascites; immunotherapy; ovarian cancer; regulatory T cells

Mesh:

Substances:

Year:  2016        PMID: 27420920     DOI: 10.1080/08820139.2016.1186689

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  4 in total

1.  Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2.

Authors:  Sascha Troschke-Meurer; Nikolai Siebert; Madlen Marx; Maxi Zumpe; Karoline Ehlert; Oliver Mutschlechner; Hans Loibner; Ruth Ladenstein; Holger N Lode
Journal:  Oncoimmunology       Date:  2019-09-08       Impact factor: 8.110

2.  Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers.

Authors:  Oliver M T Pearce; Robin M Delaine-Smith; Eleni Maniati; Sam Nichols; Jun Wang; Steffen Böhm; Vinothini Rajeeve; Dayem Ullah; Probir Chakravarty; Roanne R Jones; Anne Montfort; Tom Dowe; John Gribben; J Louise Jones; Hemant M Kocher; Jonathan S Serody; Benjamin G Vincent; John Connelly; James D Brenton; Claude Chelala; Pedro R Cutillas; Michelle Lockley; Conrad Bessant; Martin M Knight; Frances R Balkwill
Journal:  Cancer Discov       Date:  2017-12-01       Impact factor: 39.397

3.  GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study.

Authors:  Premal H Thaker; William H Bradley; Charles A Leath; Camille Gunderson Jackson; Nicholas Borys; Khursheed Anwer; Lauren Musso; Junko Matsuzaki; Wiam Bshara; Kunle Odunsi; Ronald D Alvarez
Journal:  Clin Cancer Res       Date:  2021-07-29       Impact factor: 13.801

4.  P-MAPA and Interleukin-12 Reduce Cell Migration/Invasion and Attenuate the Toll-Like Receptor-Mediated Inflammatory Response in Ovarian Cancer SKOV-3 Cells: A Preliminary Study.

Authors:  Luiz Antonio Lupi; Flávia Karina Delella; Maira Smaniotto Cucielo; Graziela Gorete Romagnoli; Ramon Kaneno; Iseu da Silva Nunes; Raquel Fantin Domeniconi; Marcelo Martinez; Francisco Eduardo Martinez; Wagner José Fávaro; Luiz Gustavo de Almeida Chuffa
Journal:  Molecules       Date:  2019-12-18       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.